Industry News
Pharmaceutical Industry News
Eli Lilly reported $98 million in…
Eli Lilly reported $98 million in second-quarter sales for Foundayo, its newly launched oral GLP-1 treatment, lagging far behind rival Novo Nordisk's Wegovy pill.
Fujifilm Biotechnologies passed…
Fujifilm Biotechnologies passed the leadership reins to Maja Pedersen, adding president to her current role as COO while former Chief Executive Lars Petersen transitions to a strategic advisor position.
AstraZeneca and Bristol Myers…
AstraZeneca and Bristol Myers Squibb do not have any ongoing discussions about a potential deal, Reuters reported Wednesday, citing a senior source close to the matter.
Weber Shandwick and Reddit…
Weber Shandwick and Reddit partnered up in a July report that aims to decode the “new health ecosystem” and the modern women’s health content discovery journey, which, as it turns out, takes place on Reddit.
The PCSK9 cholesterol drug class…
The PCSK9 cholesterol drug class has long been viewed as one of the biggest hype-to-disappointment stories in pharmaceutical history. Merck aims to flip that narrative with Lipfendra, betting the first-ever oral option can finally unlock
Years of litigation surrounding…
Years of litigation surrounding Gilead Sciences’ tenofivor-based HIV treatments have come to an end, with the California Supreme Court taking Gilead’s side in a ruling that sets a key precedent for innovative drugmakers.
As Amgen’s flagship PCSK9…
As Amgen’s flagship PCSK9 cholesterol drug Repatha enjoys a bit of a renaissance on the back of impressive cardiovascular risk reduction data last year, the company is confident it can keep that momentum running well
Johnson & Johnson has named…
Johnson & Johnson has named Tom Cavanaugh as the next leader of its innovative medicines business, beginning Sept. 1, 2026.
Pfizer will reduce its costs by…
Pfizer will reduce its costs by $2.5 billion in another round of cutbacks, which will begin next year and run through 2029. The additional cost savings swell Pfizer's program to $9.7 billion in reductions.
With Bayer’s pharma sales growth…
With Bayer’s pharma sales growth lagging behind its crop science and consumer health divisions in the second quarter, analysts once again raised the possibility of major changes to the German conglomerate’s group structure.
Book Review: ‘The Ego Trip,’ by Kimon de Greef
Kimon de Greef’s “The Ego Trip” is an enthralling, galling journey into the deeply weird underbelly of the psychedelic renaissance.
After a yearslong struggle, Jazz…
After a yearslong struggle, Jazz Pharmaceuticals has called time on Zepzelca as a second-line treatment for small cell lung cancer.
What’s the Best Way to Treat Heartburn?
Tums, Pepcid, Gaviscon — over-the-counter medications can reduce symptoms in different ways. Here’s how to find the ideal one for you.
In a milestone for IgA…
In a milestone for IgA nephropathy, Otsuka’s Voyxact has shown for the first time in a phase 3 trial that a drug can stabilize patients’ kidney function decline to the normal rate seen in healthy
Months after reports first linked…
Months after reports first linked Curium to a potential Lantheus takeover, the radiopharma players have made it official with a deal worth up to $8 billion.
Who should be a 2026 Fiercest…
Who should be a 2026 Fiercest Woman in Life Sciences? Nominations are open for women making an impact across pharma, biotech, medtech and beyond. The deadline is Sept. 18.
Supernus and Indivior have agreed…
Supernus and Indivior have agreed to merge in an all-stock transaction to form a new central nervous system-focused biopharma. They are expected to have combined revenue of $2.2 billion this year, leveraging $125 million in
Hackers recently accessed…
Hackers recently accessed Amgen’s cloud environment, stealing sensitive patient health information and proprietary company data, the company disclosed in a securities filing on Friday.
A week after Johnson & Johnson…
A week after Johnson & Johnson moved to resolve claims that its Johnson’s Baby Powder caused ovarian cancer, Novartis’ generics and biosimilars spinout Sandoz is plotting its own escape from long-running U.S. litigation, this time
Gerresheimer, a Germany-based…
Gerresheimer, a Germany-based packaging company that specializes in drug delivery systems and glass and plastic packaging, sold two of its units to the private equity group Apax Partners in a deal valued at €1.5 billion